Thursday, March 28, 2024
HomeAsian NewsSingapore biotech startup mulls raising $300m via stock listing

Singapore biotech startup mulls raising $300m via stock listing



Singapore-based biotech startup Mirxes, which focuses on preventive healthcare solutions for cancer and infectious diseases, is considering an initial public offering (IPO) in the city-state next year, possibly as Bloomberg News reported, citing people familiar with the matter. Raised about $300 million. matter. The company is in discussions with bankers over a potential offering worth more than $1 billion, the report said, adding that deliberations are still ongoing. Analysts said any listing would help further stimulate Singapore’s IPO market. So far this year, the city-state’s first-time stock sales totaled $348 million, up from $242 million…

Singapore-based biotech startup Mirxes, which focuses on preventive healthcare solutions for cancer and infectious diseases, is considering an initial public offering (IPO) in the city-state next year that could raise about $300 million, Bloomberg News Citing someone with knowledge of the matter.

The company is in discussions with bankers over a potential offering worth more than $1 billion, the report said, adding that deliberations are still ongoing.

Analysts said any listing would help further stimulate Singapore’s IPO market. First-time stock sales in the city-state have totaled $348 million so far this year, up from $242 million a year earlier, according to data compiled by Bloomberg.

Potential for microRNA applications

According to its website, Mirxes, established in 2014 as an affiliate of the Singapore government-backed science, technology and research agency, develops solutions for the early detection of multiple cancers using a proprietary RNA-powered blood test.

The company said its founders pioneered a specific technology to analyze microRNAs, the smallest genetic material found in humans and other organisms, unlocking the potential for microRNA-based clinical applications to address “cancer, cardiovascular, metabolic and infectious diseases.” disease unmet needs.”

The startup raised $87 million in a Series C round in 2021, bringing the total raised since its inception to $130 million.

Mirxes has operations in China, Japan and the United States, and has commercial activities in more than 45 countries. In 2020, the startup joined other companies in its efforts to mass-produce Singapore’s first licensed Covid-19 PCR test, with more than 8 million kits deployed globally.



Support ASEAN News

Investvine has been the unanimous voice of ASEAN news for over a decade. From breaking news to exclusive interviews with key ASEAN leaders, we bring you authentic and engaging coverage for free – the stories that matter.

Like many news organizations, we are struggling to survive in an era of reduced advertising and biased news. Our mission is to transcend today’s challenges and portray tomorrow’s world through clear, reliable reporting.

Support us now with a donation of your choice. Your contributions will help us uncover important ASEAN stories, reach more people, and elevate the diverse voices of this dynamic, influential region.



Source link

RELATED ARTICLES

Most Popular

Recent Comments